Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination by Sakamoto, Shinjiro et al.
広島大学学術情報リポジトリ
Hiroshima University Institutional Repository
Title Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized
peptide vaccination
Auther(s) Sakamoto, Shinjiro; Yoshitomi, Munehiro; Yutani, Shigeru;Terazaki, Yasuhiro; Yoshiyama, Koichi; Ioji, Tetsuya;
Matsueda, Satoko; Yamada, Akira; Takamori, Shinzo; Itoh,
Kyogo; Hattori, Noboru; Kohno, Nobuoki; Sasada, Tetsuro
Citation Human Vaccines & Immunotherapeutics , 11 (12) : 2784 - 2789
Issue Date 2015-12-23
DOI 10.1080/21645515.2015.1075107
Self DOI
URL http://ir.lib.hiroshima-u.ac.jp/00048659
Right © Cancer Vaccine Center, Kurume University. This is anOpen Access article distributed under the terms of the
Creative Commons Attribution-Non-Commercial License
(http://creativecommons.org/licenses/by-nc/3.0/), which
permits unrestricted non-commercial use, distribution, and
reproduction in any medium, provided the original work is
properlycited. Themoral rights of the named author(s) have
been assertted.
Relation

Evaluation of prognostic significance
of granulocyte-related factors in cancer patients
undergoing personalized peptide vaccination
Shinjiro Sakamoto1,2,3,y,*, Munehiro Yoshitomi4,y, Shigeru Yutani2, Yasuhiro Terazaki4, Koichi Yoshiyama4, Tetsuya Ioji2,
Satoko Matsueda2, Akira Yamada1, Shinzo Takamori4, Kyogo Itoh2, Noboru Hattori3, Nobuoki Kohno3, and Tetsuro Sasada2,5,*
1Research Center for Innovative Cancer Therapy; Kurume University; Kurume, Japan; 2Cancer Vaccine Center; Kurume University; Kurume, Japan; 3Department of Molecular and
Internal Medicine; Institute of Biomedical & Health Sciences; Hiroshima University; Hiroshima, Japan; 4Department of Surgery; Kurume University School of Medicine;
Kurume, Japan; 5Kanagawa Cancer Center Research Institute; Yokohama, Japan
yThese authors equally contributed to this work.
Keywords: ARG1, biomarker, MMP-9, MPO, multivariate Cox regression analysis, personalized peptide vaccine
Since cancer vaccines do not always elicit beneficial effects in treated patients, identification of biomarkers for
predicting clinical outcomes would be highly desirable. We previously reported that abnormal granulocytes present in
peripheral blood mononuclear cells (PBMC) may contribute to poor prognosis in advanced prostate cancer patients
receiving personalized peptide vaccination (PPV). In the current study, we examined whether soluble factors derived
from granulocytes, such as matrix metalloproteinase 9 (MMP-9), myeloperoxidase (MPO), and arginase 1 (ARG1), and
inhibitory cytokine TGFb in pre-vaccination plasma were useful for predicting prognosis after PPV in advanced cancer
patients. In biliary tract cancer (nD25), multivariate Cox regression analysis demonstrated that patients with higher
plasma MMP-9 levels had a significantly worse overall survival (OS) [hazard ratio (HR) D 4.637, 95% confidence interval
(CI) D 1.670 - 12.877, P D 0.003], whereas MPO, ARG1, or TGFb levels were not correlated with OS. Similarly, patients
with higher MMP-9 levels showed worse prognosis than those with lower MMP-9 levels in other types of advanced
cancers, including non-small cell lung cancer (nD32, P D 0.037 by log-rank test), and pancreatic cancer (nD41, P D
0.042 by log-rank test). Taken together, plasma MMP-9 levels before vaccination might be potentially useful as a
biomarker for selecting advanced cancer patients who would benefit from PPV.
Introduction
Although recent advances in chemotherapies and/or targeted
therapies have helped to improve clinical outcomes in patients
with various types of advanced cancers, the prognosis of cancer
patients at a refractory stage still remains very poor.1-3 Therefore,
the development of new therapeutic approaches, including cancer
vaccines, would be highly desirable.4-7 Although many clinical
trials of cancer vaccines were conducted for advanced cancer
patients, most of them have failed to demonstrate any meaning-
ful therapeutic benefit over existing treatments.4-7 Since current
cancer vaccines do not elicit beneficial effects in all of the treated
patients, identification of biomarkers for predicting clinical out-
comes would be highly desirable.8,9
We have developed a new approach of peptide-based vaccina-
tion, named “personalized peptide vaccination (PPV),” in which
vaccine antigens are individually selected and administered based
on pre-existing host immunity before vaccination.10,11 We have
shown promising results of PPV in various types of advanced can-
cers.11-16 Recently, we have reported that abnormal granulocyte
signature, which was assessed by DNA microarray analysis in
peripheral blood mononuclear cells (PBMC), may contribute to
decreased overall survival (OS) in advanced castration-resistant
prostate cancer (CRPC) patients receiving PPV.17 The patients
with higher mRNA expression of granulocyte-related genes, such
as matrix metalloproteinase 9 (MMP-9), myeloperoxidase (MPO),
and arginase 1 (ARG1), showed poorer prognosis than those with
lower mRNA expression.17 In the current study, we further exam-
ined whether assessment of soluble factors derived from these
granulocyte-related genes, MMP-9, MPO, and ARG1, and inhibi-
tory cytokine TGFb in pre-vaccination plasma were useful for pre-
dicting prognosis after PPV in patients with advanced cancers,
including biliary tract cancer (BTC), non-small cell lung cancer
(NSCLC), and pancreatic cancer (PC). Our results suggested that
analysis of plasma MMP-9 would be informative for selecting can-
cer patients, who would likely benefit from PPV.
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Results
Prognostic significance of MMP-9, MPO, ARG1, and
TGFb in advanced BTC patients undergoing PPV
We previously analyzed pre-vaccination clinical findings or
laboratory data, including complete blood counts, serum bio-
chemistry tests, cytokines, and inflammation markers, to identify
potential prognostic biomarkers in advanced BTC patients
undergoing PPV (n D 25).14 The multivariate Cox regression
analysis demonstrated that lower IL-6 and higher albumin levels
before vaccination and greater numbers of peptides selected for
vaccination were significantly favorable factors for OS.14 In the
current study, we further assessed prognostic significance of other
soluble factors, including MMP-9, MPO, ARG1, and TGFb, in
pre-vaccination blood samples from the same cohort of BTC
patients (n D 25). The levels of MMP-9 were highly correlated
with those of MPO (Spearman rank correlation coefficient,
0.6954; p D 0.0001), but no correlations were observed between
other factors.
As shown in Table 1, univariate Cox regression analysis
showed that the levels of MMP-9 (P D 0.003) and MPO (P
D 0.049), but not ARG1 (P D 0.641) or TGFb (P D 0.239),
in pre-vaccination blood samples were significantly associated
with OS. After dividing the patients into 2 subgroups accord-
ing to the median value of these factors, the survival curves
were estimated by the Kaplan-Meier method with the log-rank
test. The patients with higher MMP-9 (P D 0.021) or MPO
(P D 0.018) levels in the pre-vaccination samples showed
worse prognosis than those with lower levels (Fig. 1A, B).
However, there were no statistical differences in OS between
higher and lower subsets of plasma ARG1 (P D 0.898) or
TGFb (P D 0.489) levels (Fig. 1C, D).
Furthermore, multivariate Cox regression analysis was per-
formed to precisely define the clinical significance of MMP-9
and MPO by adjusting for possible confounding factors. In addi-
tion to MMP-9 and MPO, only the factors with prognostic asso-
ciation in the univariate analysis, including hemoglobin,
albumin, IL-6, CRP, and the numbers of peptides selected for
vaccination (P D 0.039, P D 0.008, P D 0.002, P D 0.004, and
P D 0.039, respectively), were used for the multivariate analysis
(Table 1). Patients with higher MMP-9 and IL-6 levels in pre-
vaccination plasma and those with smaller numbers of antigen
peptides selected for vaccination showed a significantly worse OS
[hazard ratio (HR) D 4.637, 95% confidence interval (CI) D
1.670 – 12.877, P D 0.003; HR D 1.186, 95% CI D 1.058 –
1.327, P D 0.003; HR D 0.326, 95% CI D 0.124 – 0.856, P D
0.023; respectively] (Table 1).
Prognostic significance of MMP-9, MPO, ARG1, and
TGFb in advanced NSCLC patients undergoing PPV
We next assessed the prognostic significance of MPO, MMP-
9, ARG1, and TGFb in advanced NSCLC patients undergoing
PPV (n D 32).15 Patients were divided into 2 subgroups accord-
ing to the median value of these factors. The survival curves were
estimated by the Kaplan-Meier method, and differences in sur-
vival functions were compared using the log-rank test. The
patients with higher MMP-9 levels in the pre-vaccination plasma
showed worse prognosis than those with lower levels (P D 0.037)
(Fig. 2A). However, there were no statistical differences in OS
between higher and lower groups of MPO (P D 0.466), ARG1
(P D 0.565) or TGFb (P D 0.592) levels (Fig. 2B, C, D)
Prognostic significance of MMP-9 and MPO in advanced
PC patients undergoing PPV
We also assessed the prognostic significance of MPO and
MMP-9 in advanced PC patients undergoing PPV (n D 41).16
The patients with higher MMP-9 levels in the pre-vaccination
plasma showed worse prognosis than those with lower levels
(P D 0.042) (Fig. 3A). However, there was no statistical differ-
ence in OS between higher and lower groups of MPO
(P D 0.538) (Fig. 3B)
Discussion
Since not all patients show clinical benefits from cancer
immunotherapies, it would be critical to identify prognostic or
predictive biomarkers for patients receiving such therapies. In
previous clinical trials, several post-vaccination biomarkers,
including CTL responses, Th1 responses, delayed-type hypersen-
sitivity (DTH), autoimmunity, and anti-peptide humoral
responses, have been reported to be associated with clinical
Table 1. Univariate and multivariate analyses with pre-vaccination clinical findings and laboratory data in BTC (n = 25)
Univariate analysis Multivariate analysis
Factor Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Hemoglobin (g/dl) 0.618 (0.392 – 0.976) 0.039
Albumin (g/dl) 0.158 (0.041 – 0.616) 0.008
IL-6 (pg/ml) 1.159 (1.055 – 1.274) 0.002 1.186 (1.058 – 1.327) 0.003
CRP (mg/ml) 1.533 (1.143 – 2.056) 0.004
Number of selected peptides 0.395 (0.163 – 0.953) 0.039 0.326 (0.124 – 0.856) 0.023
MMP-9 (mg/ml) 4.252 (1.647 – 10.975) 0.003 4.637 (1.670 – 12.877) 0.003
MPO (mg/ml) 2.080 (1.003 – 4.315) 0.049
ARG1 (mg/ml) 1.002 (0.993 – 1.011) 0.641
TGFb (ng/ml) 0.741 (0.450 – 1.220) 0.239
Abbreviations: BTC, biliary tract cancer; CI, confidence interval; CRP, C-reactive protein; MPO, myeloperoxidase; ARG1, arginase 1
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responses.8,9,18-20 However, there
are currently no validated pre-vac-
cination predictive biomarkers in
widespread use. Previously, we
analyzed gene expression profiles
by DNA microarray in pre-vacci-
nation PBMC from CRPC
patients treated with PPV, and
demonstrated that granulocyte-
related gene signature in PBMC,
which included MMP-9, MPO
and ARG1, might be related to
poorer prognosis in the vaccinated
patients.17 In the current study,
we addressed the prognostic signif-
icance of granulocyte-related solu-
ble factors, including MMP-9,
MPO, and ARG1, in pre-vaccina-
tion plasma.
The current study demon-
strated that higher MMP-9 levels
in pre-vaccination plasma were
significantly associated with unfa-
vorable OS in all types of cancers
tested, including BTC, NSCLC,
and PC, suggesting that measure-
ment of plasma MMP-9 levels
might be potentially useful for
selecting cancer patients, who
would benefit from PPV. Never-
theless, since plasma MMP-9 has
been reported to be increased in
patients with various types of cancers,21-23 it is possible that
MMP-9 might has only prognostic, but not predictive, utility in
cancer patients undergoing PPV. To more clearly assess the rela-
tionship between plasma MMP-9 levels and OS and to elucidate
prognostic vs. predictive relevance of this biomarker, further
studies should be conducted in future randomized, controlled
clinical trials with or without PPV.
MMP-9 is one of the metalloproteinases, which play impor-
tant roles in cancer progression.24-26 MMP-9 degrades a variety
of extracellular matrix proteins, such as type IV collagen and gela-
tin, and accelerates tumor invasion and metastasis. MMP-9 also
activates chemokines and/or growth factors for assisting tumor
growth.24-26 In addition, MMP-9 is implicated in the release and
mobilization of vascular endothelial growth factor (VEGF),
which facilitates angiogenesis and potentiates neovascularization
in tumor tissues.24-26 Since VEGF has also been reported to con-
tribute to various immunosuppressive mechanisms, such as
induction of regulatory T cells and myeloid-derived suppressor
cells (MDSC), blockade of dendritic cell (DC) maturation, Th2
polarization and production of immunosuppressive cytokines,
and blockade of intratumor T-cell infiltration,25,26 it is possible
that VEGF induction mediated by MMP-9 might be related to
impaired immune responses and poorer patient survival after
PPV. Therefore, VEGF-targeted therapy, such as anti-VEGF
antibody and tyrosine kinase inhibitors of VEGF receptor, might
be beneficial for treating the cancer patients with higher MMP-9
expression, who might show increased VEGF level and activity.
In the current study, plasma MMP-9 levels were significantly
associated with OS in all types of cancers tested. However,
plasma MPO levels were significantly associated with OS only in
BTC, but not in NSCLC or PC. In addition, plasma ARG1
showed no prognostic significance in cancers tested. Although all
of these soluble factors are reported to be produced by neutro-
phils, including granulocytic MDSC,17,27,28 the prognostic sig-
nificance seems to be different among them. This discreapancy
might be explained by the fact that the plasma concentrations of
each factor might be substantially affected by other sources of
production and secretion.24,26,28
The current study has several shortcomings and limitations.
First, this is a small study with a limited number of patients, all
of whom received PPV. Therefore, clinical value of MMP-9 mea-
surement in pre-vaccination plasma remains to be confirmed in
future larger-scale, prospective trials conducted in patients with
or without receiving PPV. Second, the mechanism underlying
the correlation between increase in MMP-9 and poorer prognosis
after PPV remains to be clarified. We proposed a potential expla-
nation associated with VEGF, but could not provide any evi-
dence for supporting it. Although it would be quite interesting to
Figure 1. Prognostic significance of plasma MMP-9, MPO, ARG1, and TGFb in advanced BTC patients treated
with PPV. To examine the prognostic significance of MMP-9, MPO, ARG1, and TGFb in pre-vaccination
plasma from advanced BTC patients treated with PPV (n D 25), curves for OS were estimated by the Kaplan-
Meier method, and differences between survival curves were statistically analyzed using the log-rank test.
Censored patients are shown as vertical bars. Patients treated with PPV were divided into 2 subgroups
according to the median values of plasma MMP-9 (A), MPO (B), ARG1 (C), and TGFb (D).
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measure the values of VEGF in blood from the vaccinated
patients, we could not do in this study. Since VEGF has been
reported to be especially unstable after cryopreservation,29 it
should be quantitated using fresh blood samples that have never
been frozen. Nevertheless, fresh blood samples that have never
been frozen and can be used for measurement of VEGF levels
were unavailable from the vaccinated patients in this study. It
would be quite important to clarify the association between
MMP-9 and VEGF levels by using fresh blood samples from vac-
cinated patients in future studies.
In summary, the current study demonstrated that plasma
MMP-9 levels may be a potentially prognostic factor for PPV.
Further prospective clinical trials of PPV would be warranted to
investigate whether evaluation of plasma MMP-9 levels before
vaccination is useful for selecting patients who would benefit
from PPV in cancer patients. In addition, it would also be inter-
esting to examine any potential utility of MMP-9 as a prognos-
tic marker in patients receiving other cancer vaccines. Since
cancer vaccines generally take effect by the immune-related
mechanisms similar to those of PPV, it might be possible that
higher MMP-9 levels in pre-vaccination plasma might also be
related to poorer prognosis even in patients with other cancer
vaccines.
Patients and Methods
Patients
This is a retrospective analysis
with peripheral blood samples
from the patients with BTC (n D
25), NSCLC (n D 32), and PC (n
D 41), who were enrolled in phase
II clinical trials for PPV.14-16
These studies were approved
by the Kurume University
Ethical Committee, and were reg-
istered in the UMIN Clinical Tri-
als Registry (UMIN000002907,
UMIN000001839, and
UMIN000001881). Patients were
eligible for inclusion in the current
study if they had a histological
diagnosis of BTC, NSCLC, or
PC, and showed positive humoral
responses to at least 2 of the 31
different vaccine candidate pepti-
des. Other inclusion criteria and
exclusion criteria and study proto-
cols were reported previously.14-16
After a full explanation of the pro-
tocol, written informed consent
was obtained from all patients
before enrollment.
Clinical protocol
All patients with BTC,
NSCLC, and PC were treated by
the same clinical protocol, as follows. Thirty-one peptides were
employed for vaccination [12 peptides for HLA-A2, 16 peptides
for HLA-A24, 9 peptides for HLA-A3 supertypes (-A3, -A11,
-A31, and -A33), and 4 peptides for HLA-A26].14-16 Vaccine
peptides adequate to individual patients were selected in consid-
eration of the pre-existing host immunity before vaccination, as
assessed by the results of HLA typing and the titers of IgG spe-
cific to each of the 31 different vaccine candidates. A maximum
of 4 peptides (3 mg/each peptide), which were selected, were
subcutaneously administrated with incomplete Freund’s adjuvant
(Montanide ISA51; Seppic, Paris, France) once a week for 6 con-
secutive weeks as the 1st cycle. After the 1st cycle of vaccinations,
up to 4 antigen peptides that were re-selected according to the
titers of peptide-specific IgG were administered biweekly for
6 times. After the 2nd cycle of vaccinations, up to 4 antigen pep-
tides that were re-selected every 6 times of vaccinations were
administered every 4 weeks.
Measurement of soluble factors in plasma
Plasma samples were obtained from the enrolled patients
before vaccination. To detect the levels of MMP-9, MPO, and
TGFb in plasma, a bead-based multiplex assay (Luminex
200TM system; Luminex Corporation, Austin, TX) was used.
Figure 2. Prognostic significance of plasma MMP-9, MPO, ARG1, and TGFb in advanced NSCLC patients
treated with PPV. To examine the prognostic significance of MMP-9, MPO, ARG1, and TGFb in pre-vaccina-
tion plasma from advanced NSCLC patients treated with PPV (n D 32), curves for OS were estimated by the
Kaplan-Meier method, and differences between survival curves were statistically analyzed using the log-rank
test. Censored patients are shown as vertical bars. Patients treated with PPV were divided into 2 subgroups
according to the median values of plasma MMP-9 (A), MPO (B), ARG1 (C), and TGFb (D).
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The analyte kit used for the measurement was obtained from
Millipore (Billerica, MA). The levels of ARG1, CRP, and IL-6 in
plasma were examined by using an ELISA kit from BioVendor
(Candler, MN), R&D systems (Minneapolis, MN), and eBio-
science (San Diego, CA), respectively. Frozen plasma samples
were thawed, diluted, and assayed in duplicate in accordance
with the manufacturer’s instructions. The mean of duplicate
samples was used for statistical analysis. Complete blood counts
and serum biochemistry tests were also performed before
vaccinations.
Statistical Analysis
OS time was calculated from the first day of peptide vaccina-
tion until the date of death or the last date when the patient was
known to be alive. Association between pre-vaccination clinical
findings or laboratory data and OS were evaluated by univariate
and multivariate analyses with the
Cox proportional hazards regres-
sion model in BTC patients
undergoing PPV. Curves for OS
were also estimated by the
Kaplan-Meier method, and differ-
ences in survival functions were
compared using the log-rank test
in BTC, NSCLC, and PC patients
undergoing PPV. The strength of
relationship between soluble fac-
tors was evaluated by Spearman’s
rank correlation coefficient. All
tests were 2-sided, and differences
at P < 0.05 were considered to be
statistically significant. All of the
statistical analyses were conducted
using the JMP version 10 or SAS
version 9.3 software package (SAS
Institute Inc.., Cary, NC).
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